Today,
In 2015, the perfusionist team and the transplant team at GOSH in
In 2021,
The symposium "Intraoperative anti-A / B immunoadsorption for ABO-incompatible transplantation" is held digitally / virtually (link).
In the symposium the ex-vivo model used to create the methodology will be discussed, as well as the first case series of patients transplanted, comparing the outcomes with those undergoing treatment with the previously used method. Finally, a case study will be used to illustrate how intraoperative Glycosorb® ABO is pushing the boundaries of who can undergo a pediatric blood group incompatible heart transplantation.
-
Robertson A, Issitt R, Crook R, Gustafsson K, Eddaoudi A, Tsang V, Burch M; A novel method for ABO-incompatible heart transplantation J Heart Lung Transplant. 2018 Apr;37(4):451-457. doi: 10.1016/j.healun.2017.05.006.Epub 2017
May 5 .
-
Issitt R, Crook R, Shaw M, Robertson A; The
Great Ormond Street Hospital immunoadsorption method for ABO-incompatible heart transplantation: a practical technique
Perfusion 2021 Jan;36(1):34-37. doi: 10.1177/0267659120926895. Epub 2020Jun 3 .
- Issitt R, Booth J, Crook R, Robertson A, Molyneux V, Richardson R, Cross N, Shaw M, Tsang V, Muthurangu V, Sebire NJ, Burch M, Fenton M. Intraoperative anti-A/B immunoadsorption is associated with significantly reduced blood product utilization with similar outcomes in pediatric ABO-incompatible heart transplantation. J Heart Lung Transplant. 2021 May 29:S1053-2498(21)02325-1.
Contact
E-mail: info@glycorex.se, phone: 046-286 52 30
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-sponsors-a-digital-symposium-on-intraoperative-glycosorb--abo-treatment-in-,c3534715
https://mb.cision.com/Main/15286/3534715/1555566.pdf
(c) 2022 Cision. All rights reserved., source